Expertise in
4
conditions

Jishi L. Wang

Guiyang, CN 
Clinical Trials:Currently Recruiting for 1 Trial
Expertise in
4
conditions
Guiyang, CN 

Overview

Jishi Wang practices practicing medicine in Guiyang, China.

Wang is highly rated in 4 conditions, according to our data. Their clinical expertise encompasses Leukemia, Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), Bone Marrow Transplant, and Bone Marrow Aspiration.

They are actively involved in clinical research, co-authoring 167 peer reviewed articles and participating in 4 clinical trials.

Locations

Guiyang, China
Other Locations
Key Laboratory Of Hearing Medicine, Shanghai, 200031, China
China
Union Hospital, Tongji, 430022, China
Suzhou, China
Xinhua, 200092, China
Changzhou, 213003, China
Department Of Otorhinolaryngology Head And Neck Surgery, Xi'an, 710032, China
Baise City, China
Guangzhou, China
Weifang, China
Weifang, China
Nanjing, 210000, China

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

4 Clinical Trials

A Single-arm, Pivotal Registration Phase II Study of the Efficacy and Safety of APG-2575 Monotherapy in Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
A Single-arm, Pivotal Registration Phase II Study of the Efficacy and Safety of APG-2575 Monotherapy in Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Enrollment Status: Recruiting
Publish Date: March 27, 2026
Intervention Type: Drug
Study Drug: APG2575
Study Phase: Phase 2
Hematopoietic Stem Cell Transplantation for Patients With Thalassemia Major: A Multicenter, Prospective Clinical Study
Hematopoietic Stem Cell Transplantation for Patients With Thalassemia Major: A Multicenter, Prospective Clinical Study
Enrollment Status: Completed
Publish Date: August 09, 2024
Intervention Type: Drug
Study Drugs: Busulfan, Cyclophosphamide, Fludarabine, Thymoglobulin, Cyclosporine A, Mycophenolate mofetil, Tacrolimus, Methotrexate, Basiliximab, Ruxolitinib
Study Phase: Phase 4
A Multicenter, Open-label, Phase 1/2a Study to Evaluate the Safety and Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of TJ011133 as Monotherapy and in Combination With Azacitidine (AZA) in Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
A Multicenter, Open-label, Phase 1/2a Study to Evaluate the Safety and Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of TJ011133 as Monotherapy and in Combination With Azacitidine (AZA) in Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
Enrollment Status: Completed
Publish Date: April 15, 2024
Intervention Type: Drug
Study Drugs: TJ011133, Azacitidine
Study Phase: Phase 1/Phase 2
A Single-arm, Open-label, Multi-center Phase Ib/II Study of TQ-B3525 in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma(CLL/SLL)
A Single-arm, Open-label, Multi-center Phase Ib/II Study of TQ-B3525 in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma(CLL/SLL)
Enrollment Status: Terminated
Publish Date: November 29, 2023
Intervention Type: Drug
Study Drug: TQ-B3525
Study Phase: Phase 1/Phase 2
View 3 Less Clinical Trials

166 Total Publications

Evaluating comorbidity scoring systems for flumatinib therapy in chronic myeloid leukemia: a machine learning and SHAP-based predictive analysis.
Evaluating comorbidity scoring systems for flumatinib therapy in chronic myeloid leukemia: a machine learning and SHAP-based predictive analysis.
Journal: Frontiers in medicine
Published: April 07, 2026

Frequently Asked Questions about Jishi L. Wang

Is Jishi L. Wang a top-rated expert for Leukemia?

MediFind is an objective health platform that identifies experts based on real-world data. Jishi L. Wang is classified as an Distinguished expert for Leukemia, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Jishi L. Wang participate in research or clinical trials?

Yes. Jishi L. Wang has published 166 articles and abstracts on conditions like Leukemia. You can view a list of Jishi L. Wang's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Wang's expertise for a condition
ConditionClose
    View All 23 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile